- About tgcBIOMICS
- Clostridium difficile
- Company profile
- Contract research and development
- EU research projects
- Job offers
- NEWS & Press
- Our products
- tgcBIOMICS Technology
- Welcome to tgcBIOMICS!
In many clinical cases, it is important to conduct an additional ribotyping by using step diagnostics once a positive finding of the Clostridium difficile infection has been determined. Depending on the ribotype, certain epidemiological and therapeutic measures can be deduced.
tgcBIOMICS has developed new gene technology methods for diagnosing Clostridium difficile which assist in a definitive diagnosis that can be made within a period of a few days.
tgcBIOMICS Bingen supports the diagnostic work of the Robert Koch Institut (RKI, Berlin).
Important sources come, for example, from the departments of health which are directly associated with research for local outbreaks. In the future, the specification of mutants will gain significantly more importance since experts predict that the 027 mutants will be spreading further.